Prevalence of Incidental Findings Suspicious for Transthyretin Cardiac Amyloidosis among Patients Undergoing Bone Scintigraphy: A Systematic Review and a Meta-Analysis.
amyloidosis
bone scan
cardiac uptake
incidental
meta-analysis
nuclear medicine
scintigraphy
transthyretin
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
01 Sep 2023
01 Sep 2023
Historique:
received:
24
07
2023
revised:
13
08
2023
accepted:
29
08
2023
medline:
9
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
The myocardial uptake of bone-seeking tracers suspicious for transthyretin cardiac amyloidosis (ATTR-CA) can be incidentally detected in patients undergoing bone scintigraphy for noncardiac reasons. We conducted a systematic review and meta-analysis to assess the prevalence of these scintigraphic findings. A comprehensive literature search was performed using two bibliographic databases (PubMed/MEDLINE and Cochrane Library), searching for articles related to the review question. Eligible articles were selected, and relevant data were extracted by two authors. The pooled prevalence of incidental findings suspicious for ATTR-CA among patients undergoing bone scintigraphy was calculated on a per-patient-based analysis using a random-effects model. The pooled measure was provided with 95% confidence interval (95% CI) values. Among 219 records, 11 articles were selected for the systematic review and 10 for the meta-analysis. The pooled prevalence of incidental findings suspicious for ATTR-CA was 1.1% (95% CI: 0.7-1.4%) with heterogeneity due to the characteristics of the included studies, patients, and index tests. These findings are more prevalent in older men. The prevalence of incidental findings of ATTR-CA among patients undergoing bone scintigraphy is low but not negligible. Nuclear medicine physicians should suggest, in the scintigraphic report, further clinical investigations when these findings are detected. Prospective studies are warranted.
Sections du résumé
BACKGROUND
BACKGROUND
The myocardial uptake of bone-seeking tracers suspicious for transthyretin cardiac amyloidosis (ATTR-CA) can be incidentally detected in patients undergoing bone scintigraphy for noncardiac reasons. We conducted a systematic review and meta-analysis to assess the prevalence of these scintigraphic findings.
METHODS
METHODS
A comprehensive literature search was performed using two bibliographic databases (PubMed/MEDLINE and Cochrane Library), searching for articles related to the review question. Eligible articles were selected, and relevant data were extracted by two authors. The pooled prevalence of incidental findings suspicious for ATTR-CA among patients undergoing bone scintigraphy was calculated on a per-patient-based analysis using a random-effects model. The pooled measure was provided with 95% confidence interval (95% CI) values.
RESULTS
RESULTS
Among 219 records, 11 articles were selected for the systematic review and 10 for the meta-analysis. The pooled prevalence of incidental findings suspicious for ATTR-CA was 1.1% (95% CI: 0.7-1.4%) with heterogeneity due to the characteristics of the included studies, patients, and index tests. These findings are more prevalent in older men.
CONCLUSIONS
CONCLUSIONS
The prevalence of incidental findings of ATTR-CA among patients undergoing bone scintigraphy is low but not negligible. Nuclear medicine physicians should suggest, in the scintigraphic report, further clinical investigations when these findings are detected. Prospective studies are warranted.
Identifiants
pubmed: 37685765
pii: jcm12175698
doi: 10.3390/jcm12175698
pmc: PMC10488435
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
JACC Cardiovasc Imaging. 2023 Aug;16(8):1085-1095
pubmed: 37227330
J Nucl Cardiol. 2022 Dec;29(6):3419-3425
pubmed: 35437680
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Card Fail Rev. 2023 May 25;9:e08
pubmed: 37427006
JACC Cardiovasc Imaging. 2014 May;7(5):531-2
pubmed: 24831216
AJR Am J Roentgenol. 2023 Jun 14;:
pubmed: 37315017
J Cardiovasc Dev Dis. 2023 May 31;10(6):
pubmed: 37367407
Radiology. 2023 Feb;306(2):e221082
pubmed: 36537896
Front Cardiovasc Med. 2023 Mar 09;10:1146725
pubmed: 36970351
J Am Coll Cardiol. 2016 Jul 12;68(2):161-72
pubmed: 27386769
Biomedicines. 2022 Jun 30;10(7):
pubmed: 35884871
Cells. 2021 Jul 13;10(7):
pubmed: 34359938
Annu Rev Med. 2020 Jan 27;71:203-219
pubmed: 31986086
J Nucl Med. 2022 Dec;63(12):1906-1911
pubmed: 35710734
Int J Cardiol. 2018 Nov 1;270:192-196
pubmed: 29903517
Int Heart J. 2019 May 30;60(3):643-647
pubmed: 31019172
Circ Cardiovasc Imaging. 2021 Jul;14(7):e000030
pubmed: 34196222
Eur J Nucl Med. 1995 Feb;22(2):148-53
pubmed: 7758502
J Nucl Cardiol. 2022 Jun;29(3):1021-1029
pubmed: 33094472
Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):17-26
pubmed: 35414855
Swiss Med Wkly. 2021 Oct 20;151:w30053
pubmed: 34694105
Int J Cardiovasc Imaging. 2023 Jul;39(7):1397-1404
pubmed: 37005954
Circ Cardiovasc Imaging. 2021 Jul;14(7):e000029
pubmed: 34196223
Amyloid. 2022 Jun;29(2):120-127
pubmed: 35023433
J Nucl Cardiol. 2021 Jun;28(3):825-830
pubmed: 33728572
Cardiol Clin. 2023 May;41(2):217-231
pubmed: 37003679
EJNMMI Res. 2022 May 7;12(1):27
pubmed: 35524861
J Clin Epidemiol. 2021 Jun;134:178-189
pubmed: 33789819
Heart Fail Rev. 2022 Sep;27(5):1471-1484
pubmed: 34694575
Eur Heart J. 2021 Apr 21;42(16):1554-1568
pubmed: 33825853
J Nucl Cardiol. 2021 Dec;28(6):2845-2856
pubmed: 32385832
Swiss Med Wkly. 2020 Dec 05;150:w20364
pubmed: 33277911
Eur Heart J. 2019 Apr 01;:
pubmed: 30938420
Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1945-1955
pubmed: 29687207
J Nucl Med Technol. 2023 Jun;51(2):120-124
pubmed: 37192820